Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Victoza (active ingredient:liraglutide) subcutaneous injection Initial FDA Approval: 2010 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
)
Subcutaneous injections are preferred for most peptide therapies, as they are generally easier and less painful
Hepatology 1999
.jpg)
[2] Advanced cirrhosis: Patients with borderline hepatic encephalopathy are at high risk of oversedation
Compounded semaglutide and tirzepatide from licensed 503A pharmacies typically range $149/mo monthly, depending on dose and frequency, with no middleman markup
